Corley Douglas A, Kubo Ai, Levin Theodore R, Habel Laurel, Zhao Wei, Leighton Patricia, Rumore Gregory, Quesenberry Charles, Buffler Patricia, Block Gladys
Division of Research, Kaiser Permanente, Oakland, California 94612, USA.
Am J Gastroenterol. 2008 Dec;103(12):2997-3004. doi: 10.1111/j.1572-0241.2008.02156.x. Epub 2008 Oct 1.
High iron stores are a proposed modifiable risk factor for esophageal adenocarcinoma, but minimal human data exist. We evaluated whether iron intake and iron stores were associated with Barrett's esophagus, a metaplastic change that is a strong risk factor for esophageal adenocarcinoma.
We conducted a case-control study within the Kaiser Permanente Northern California population. We identified all persons with a new diagnosis of Barrett's esophagus (cases); they were matched to persons with GERD (without Barrett's esophagus) and to population controls. Subjects completed examinations, dietary questionnaires, and testing for serum iron stores (ferritin and transferrin saturation). Analyses used unconditional logistic regression.
We evaluated 319 cases, 312 GERD patients, and 313 population controls. Compared with population controls, Barrett's esophagus patients had lower dietary iron intakes (4th vs 1st quartiles, odds ratio [OR]= 0.37, 95% confidence interval [CI] 0.17-0.80), similar total iron intakes (including supplement use), and lower iron stores (4th vs 1st quartiles, ferritin OR = 0.24, 95% CI 0.14-0.40;% transferrin saturation OR = 0.66, 95% CI 0.41-1.04; P value trend <0.01 and 0.03, respectively). Similar associations were observed in comparisons with GERD controls and among subjects without clear sources of blood loss on endoscopy.
Patients with Barrett's esophagus had lower dietary iron intakes and lower serum iron stores than controls in our population. These findings do not provide support for the current hypothesis that high iron stores or a high iron intake are risk factors for Barrett's esophagus, a potential early event in the carcinogenic sequence for esophageal adenocarcinoma.
高铁储存量是食管腺癌一个假定的可改变风险因素,但相关的人体数据极少。我们评估了铁摄入量和铁储存量是否与巴雷特食管相关,巴雷特食管是一种化生改变,是食管腺癌的一个重要风险因素。
我们在北加利福尼亚州凯撒医疗集团人群中开展了一项病例对照研究。我们确定了所有新诊断为巴雷特食管的患者(病例组);将他们与患有胃食管反流病(无巴雷特食管)的患者以及人群对照组进行匹配。受试者完成了检查、饮食问卷以及血清铁储存量(铁蛋白和转铁蛋白饱和度)检测。分析采用无条件逻辑回归。
我们评估了319例病例、312例胃食管反流病患者和313例人群对照。与人群对照组相比,巴雷特食管患者的饮食铁摄入量较低(第4四分位数与第1四分位数相比,比值比[OR]=0.37,95%置信区间[CI]0.17 - 0.80),总铁摄入量(包括补充剂使用)相似,且铁储存量较低(第4四分位数与第1四分位数相比,铁蛋白OR = 0.24,95% CI 0.14 - 0.40;转铁蛋白饱和度百分比OR = 0.66,95% CI 0.41 - 1.04;P值趋势分别<0.01和0.03)。在与胃食管反流病对照组的比较以及内镜检查无明显失血来源的受试者中观察到了类似的关联。
在我们的人群中,巴雷特食管患者的饮食铁摄入量和血清铁储存量均低于对照组。这些发现不支持当前关于高铁储存量或高铁摄入量是巴雷特食管风险因素的假说,而巴雷特食管是食管腺癌致癌序列中一个潜在的早期事件。